{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:10:38Z","timestamp":1790856638598,"version":"4.1.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"\n Objective<\/jats:title>\n In primary hyperparathyroidism (PHPT) with osteoporosis, bone mineral density (BMD) improves after parathyroidectomy. It is unclear whether combining surgery with postoperative bisphosphonate treatment can further improve bone health.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n This randomized, placebo-controlled study compared the effects of surgery alone and surgery combined with zoledronic acid on bone metabolism in PHPT with osteoporosis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Fifty-six patients (f\/m 47\/9, mean age 68.4 years) with PHPT and osteoporosis were randomized 1\u20133 months after parathyroidectomy to receive a 2-year treatment of zoledronic acid or placebo. Dual-energy X-ray absorptiometry (DXA) and bone turnover markers (N-terminal propeptide of type 1 procollagen, C-terminal telopeptide of type 1 collagen, and alkaline phosphatase) were measured annually during the 2-year follow-up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Two years after parathyroidectomy, BMD was significantly higher in the zoledronic acid (ZOL) group compared with the placebo (PBO) group at the femoral neck (\n P<\/jats:italic>\n \u2009=\u20090.045 for Z-score) and lumbar spine (\n P<\/jats:italic>\n \u2009=\u20090.039 and 0.017 for T- and Z-scores, respectively). Bone turnover markers were significantly lower in the ZOL group (\n P<\/jats:italic>\n < 0.001 for all markers). Of the 18 patients who had received bisphosphonates for >1 year before surgery, BMD improved significantly in the ZOL group both in the femoral neck and lumbar spine (\n n<\/jats:italic>\n \u2009=\u200910; all\n P<\/jats:italic>\n < 0.001\u20130.01), but in the PBO group, only in the lumbar spine (\n n<\/jats:italic>\n \u2009=\u20098,\n P<\/jats:italic>\n \u2009=\u20090.03), (\n P<\/jats:italic>\n = 0.08\u20130.95 for between-group changes).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n BMD increases after parathyroidectomy both with and without zoledronic acid but the increase is significantly higher with postoperative zoledronic acid.<\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/eje-21-0322","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T13:44:14Z","timestamp":1627566254000},"page":"515-524","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":23,"title":["Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study"],"prefix":"10.1093","volume":"185","author":[{"given":"E M","family":"Ryh\u00e4nen","sequence":"first","affiliation":[{"name":"1Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Koski","sequence":"additional","affiliation":[{"name":"2Endocrinology, Department of Internal Medicine, Central Finland Health Care District Hospital, Jyv\u00e4skyl\u00e4, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"L\u00f6yttyniemi","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"V\u00e4lim\u00e4ki","sequence":"additional","affiliation":[{"name":"4Aava Clinic, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Kiviniemi","sequence":"additional","affiliation":[{"name":"5Endocrinology, University of Tampere, Tampere University Hospital, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Schalin-J\u00e4ntti","sequence":"additional","affiliation":[{"name":"1Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/185\/4\/EJE-21-0322.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/185\/4\/EJE-21-0322.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:16:36Z","timestamp":1676373396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/185\/4\/515\/6654380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/eje-21-0322","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}